Insulet Corporation (PODD)
NASDAQ: PODD
· Real-Time Price · USD
325.07
1.22 (0.38%)
At close: May 30, 2025, 3:59 PM
323.79
-0.39%
After-hours: May 30, 2025, 06:39 PM EDT
Insulet Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|
| Drug Delivery Revenue | 38.9M | 36M | 57.5M | 87.4M | 69.5M | 64.7M | 72.22M | 65.31M |
| Drug Delivery Revenue Growth | +8.06% | -37.39% | -34.21% | +25.76% | +7.42% | -10.41% | +10.57% | n/a |
| International Omnipod Revenue | 2.03B | 1.66B | 1.25B | 1.01B | 834.9M | 673.5M | 391.55M | 301.67M |
| International Omnipod Revenue Growth | +22.37% | +33.12% | +23.37% | +21.14% | +23.96% | +72.01% | +29.79% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 523.4M | 410.1M | 363M | 359.9M | 308M | 253.1M | 172.02M | 119.95M | 71.89M |
| Non-Us Revenue Growth | +27.63% | +12.98% | +0.86% | +16.85% | +21.69% | +47.13% | +43.41% | +66.86% | n/a |
| United States Revenue | 1.55B | 1.29B | 942.3M | 738.9M | 596.4M | 485.1M | 391.8M | 343.81M | 295.1M |
| United States Revenue Growth | +20.30% | +36.58% | +27.53% | +23.89% | +22.94% | +23.81% | +13.96% | +16.51% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 260.6M | 261M | 234.1M | 220M | 197.3M | 212.8M | 180.7M | 178.7M | 162.7M | 144.3M | 140.4M | 174.4M | 128.7M | 121.7M | 117.5M | 116.3M | 110.5M | 130.1M | 89.2M | 80.8M | 83.9M | 81.2M | 75.3M | 76.55M | 67.48M | 65.56M | 73.34M | 59.33M | 55.9M | 61.49M | 51.44M | 49.97M | 47.21M | 49.04M | 39.49M | 38.79M | 38.76M | 56.46M | 41.35M | 34.67M | 33.23M |
| Selling, General, and Administrative Revenue Growth | -0.15% | +11.49% | +6.41% | +11.51% | -7.28% | +17.76% | +1.12% | +9.83% | +12.75% | +2.78% | -19.50% | +35.51% | +5.75% | +3.57% | +1.03% | +5.25% | -15.07% | +45.85% | +10.40% | -3.69% | +3.33% | +7.84% | -1.64% | +13.45% | +2.92% | -10.60% | +23.62% | +6.13% | -9.09% | +19.55% | +2.94% | +5.85% | -3.74% | +24.18% | +1.80% | +0.08% | -31.35% | +36.55% | +19.28% | +4.32% | n/a |
| Research and Development Revenue | 59.6M | 60.6M | 54.9M | 53.9M | 50.2M | 42M | 57.8M | 55.1M | 50.1M | 49.5M | 45M | 42.6M | 43.1M | 41.8M | 37.5M | 40.1M | 40.7M | 38.3M | 38.8M | 34.2M | 35.5M | 34.7M | 30.78M | 32.26M | 31.95M | 28.51M | 21.76M | 18.42M | 19.91M | 18.78M | 20.14M | 18.03M | 17.5M | 16.03M | 13.73M | 12.95M | 12.99M | 12.9M | 10.04M | 12.07M | 8.21M |
| Research and Development Revenue Growth | -1.65% | +10.38% | +1.86% | +7.37% | +19.52% | -27.34% | +4.90% | +9.98% | +1.21% | +10.00% | +5.63% | -1.16% | +3.11% | +11.47% | -6.48% | -1.47% | +6.27% | -1.29% | +13.45% | -3.66% | +2.31% | +12.74% | -4.60% | +0.97% | +12.06% | +31.03% | +18.16% | -7.50% | +6.02% | -6.75% | +11.71% | +3.02% | +9.14% | +16.75% | +6.03% | -0.28% | +0.71% | +28.52% | -16.85% | +47.06% | n/a |